Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
105 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-07-31
Study Completion Date
2029-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aβ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
NCT01466088
Alzheimer's Disease
COMPLETED
PHASE2
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
NCT06427668
Alzheimer Disease
ACTIVE_NOT_RECRUITING
PHASE2
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
NCT01350362
Alzheimer's Disease
COMPLETED
PHASE2
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
NCT00103649
Alzheimer Disease
COMPLETED
PHASE3
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
NCT02322021
Alzheimer Disease
Dementia, Alzheimer Type
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Alzheimer's disease (AD) is a neurodegenerative disorder with several complex neuropathologies suspected to develop sequentially but that overlap over time as symptoms progress to dementia. Thus, to be effective, future intervention strategies will likely require combination therapies or pleiotropic agents to tackle several AD molecular pathogenic pathways simultaneously. For more than a decade, our group has been exploring the repurposing of immunomodulators for AD. Recent discussions with collaborators who specialize in multiple sclerosis suggest that sphingosine-1-phosphate receptor (S1PR) modulators are strong candidates for repurposing in AD. Indeed, S1PR modulators are blood brain barrier (BBB) penetrant and display pleiotropic actions, including immunomodulation and neuroprotective properties. S1P is a versatile endogenous molecule that regulates several signaling pathways by binding to five G-protein-coupled receptors, which are expressed in high levels in cardiac, vascular, immune, and brain cells. This widespread localization of S1PR was the historical basis for Novartis Pharmaceuticals, Inc, to develop oral formulations of S1PR modulators for multiple sclerosis (MS), which proved successful and resulted in two marketed oral compounds (i.e., fingolimod and Siponimod). In the present project, we intend to collaborate with Novartis to use the most recently FDA-approved S1PR modulator, Siponimod. Based on MS and animal experimentation literature, we hypothesize that Siponimod could alter the rate of neurodegeneration as measured by lowering the rate of brain atrophy in mild AD dementia subjects. In this Phase II, proof-of-concept, translational clinical study, mild AD dementia subjects will be randomized 2:1 and will receive gradual titration regimen of Siponimod starting at 0.25mg/day and increasing up to final dosage of 1 mg/day (N=70) or placebo (N=35) for 12 months. This will be followed by a 6-month washout period. Siponimod has demonstrated positive immunomodulatory and neuroprotective actions in MS patients, and because its toxicity profile is favorable for use in older individuals, Siponimod has a strong potential to alter markers of mild AD dementia pathology and disease trajectory.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer Disease
Mild Alzheimer Disease
MCI With Increased Risk for Alzheimer Disease
Cognitive Impairment, Mild
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
The study will have 105 participants with a 2:1 ratio of drug:placebo.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
The clinical research coordinator, the psychometrist, the co-investigators (Dr. Boris Decourt and Dr. Karl Golnik) will be masked. Everyone who is patient-facing will be masked.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug Arm
Randomly assigned subjects who will receive an escalating dose of Siponimod (0.25-1 mg/day) for 12 months.
Group Type
EXPERIMENTAL
Siponimod
Intervention Type
DRUG
Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
Placebo Arm
Randomly assigned subjects who will receive a placebo daily for 12 months.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Siponimod
Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
Intervention Type
DRUG
Placebo
A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Mayzent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female at least 50 years of age, but less than 85 (84 at time of screening)
2. Females must be of non-childbearing potential or have negative pregnancy test at time of screening. Women of non-childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy or bilateral salpingectomy) or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for \>=12 months prior to the planned date of enrollment.
3. Must have a diagnosis of mild Alzheimer\'s Dementia determined by medical record review.
4. Vision and hearing must be sufficient to comply with study procedures. Be able to take oral medications.
5. Must be able to attend all study visits indicated in the schedule of visits.
6. Must have a collateral informant/study partner who has significant direct contact with the patient at least 10 hours per week and who is willing to accompany the patient to specified clinic visits, supervise administration of all study medication, and be available for telephone visits/interviews.
7. Documented Mini Mental State Exam (MMSE) score between 21-26 at Screening Visit.
8. CT or MRI scan of the brain within 12 months of enrollment showing no evidence of significant focal lesions or other pathology which could contribute to dementia. If neither a CT nor an MRI scan is available from the past 12 months, a CT scan fulfilling the requirements must be obtained before randomization.
9. Hachinski ischemic score must be \< 4.
10. Geriatric depression scale must be \< 10.
11. Prior to dosing all randomized study subjects must show proof they have received immunization to varicella (VZV IgG).
12. If the patient has a legally authorized representative (LAR), the LAR must review and sign the informed consent form. If the patient does not have a LAR, the patient must appear able to provide informed consent and must review and sign the informed consent form. In addition, the patient's informant/study partner (as defined above) must sign an informed consent form. If the LAR and the patient's informant /study partner are the same individual, he/she should sign under both designations.
2. Females must be of non-childbearing potential or have negative pregnancy test at time of screening. Women of non-childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy or bilateral salpingectomy) or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for \>=12 months prior to the planned date of enrollment.
3. Must have a diagnosis of mild Alzheimer\'s Dementia determined by medical record review.
4. Vision and hearing must be sufficient to comply with study procedures. Be able to take oral medications.
5. Must be able to attend all study visits indicated in the schedule of visits.
6. Must have a collateral informant/study partner who has significant direct contact with the patient at least 10 hours per week and who is willing to accompany the patient to specified clinic visits, supervise administration of all study medication, and be available for telephone visits/interviews.
7. Documented Mini Mental State Exam (MMSE) score between 21-26 at Screening Visit.
8. CT or MRI scan of the brain within 12 months of enrollment showing no evidence of significant focal lesions or other pathology which could contribute to dementia. If neither a CT nor an MRI scan is available from the past 12 months, a CT scan fulfilling the requirements must be obtained before randomization.
9. Hachinski ischemic score must be \< 4.
10. Geriatric depression scale must be \< 10.
11. Prior to dosing all randomized study subjects must show proof they have received immunization to varicella (VZV IgG).
12. If the patient has a legally authorized representative (LAR), the LAR must review and sign the informed consent form. If the patient does not have a LAR, the patient must appear able to provide informed consent and must review and sign the informed consent form. In addition, the patient's informant/study partner (as defined above) must sign an informed consent form. If the LAR and the patient's informant /study partner are the same individual, he/she should sign under both designations.
Exclusion Criteria
1. Taking one of the following medications: Medications for treatment of cancer or other drugs that weaken the immune system (ex. Natalizumab and Rituximab), Amiodarone, Bishydroxycoumarin, Chloramphenicol, Cimetidine, Fluconazole, Fluvastatin, Miconazole, Phenylbutazone, Sulphinpyrazone, Sulphadiazine, Sulphamethizole, Sulfamethoxazole, Sulphaphenazole, Trimethoprim, and Zafirlukast.
2. Current active infection in participants including, but not limited to, herpes zoster, herpes infection, bronchitis, sinusitis, upper respiratory infection and fungal skin infection. Siponimod may increase the risk in participants with active infections.
3. If participant received mRNA COVID-19 vaccination, must have received last dose at least 3 months prior to first dose of study drug/placebo.
4. Current evidence or history within the last 3 years of a neurological or psychiatric illness that could contribute to dementia, including (but not limited to) epilepsy, focal brain lesion, Parkinson's disease, seizure disorder, or head injury with loss of consciousness.
5. Meets DSM IV criteria for any major psychiatric disorder including psychosis, major depression and bipolar disorder.
6. Known history of self-reported alcohol and/ or substance abuse.
7. Isolated living circumstances which would prohibit a study partner from providing sufficient and credible information about the participant.
8. Poorly controlled hypertension
9. Known Atrioventricular heart block, known heart block type I-III.
10. History of myocardial infarction or signs or symptoms of unstable coronary artery disease within the last year (including revascularization procedure/angioplasty).
11. Severe pulmonary disease (including chronic obstructive pulmonary disease) requiring more than 2 hospitalizations within the past year.
12. Untreated obstructive sleep apnea.
13. Any thyroid disease (unless euthyroid on treatment for at least 6 months prior to screening). \[15\] Active neoplastic disease (except for skin tumors other than melanoma). Patients with a history of prior malignancy are eligible provided they were treated with curative intent and (i) do not require any longer any active therapy; (ii) being considered in complete remission; and (iii) after the Medical Monitor's assessment/approval of each case.
14. Prior prostate cancer or new diagnosis of prostate cancer.
15. History of multiple myeloma.
16. Absolute lymphocytopenia of \<1,000/mm3, or a history of lymphocytopenia.
17. Absolute neutropenia of \<1,000/mm3, or a history of neutropenia.
18. History of/ or current thromboembolism (including deep venous thrombosis).
19. Any clinically significant hepatic or renal disease (including presence of Hepatitis B or C surface antigen or an elevated transaminase levels of greater than 2x the upper limit of normal (ULN) or creatinine greater than 1.5 x upper limit of normal (ULN)).
20. Clinically significant hematologic or coagulation disorder including any unexplained anemia, or a platelet count less than 100,000/μL at screening.
21. Use of any investigational drug within 30 days or within five half-lives of the investigational agent, whichever is longer.
22. Unwilling or unable to undergo CT or MRI imaging.
23. In the opinion of the investigator, participation would not be in the best interest of the subject.
2. Current active infection in participants including, but not limited to, herpes zoster, herpes infection, bronchitis, sinusitis, upper respiratory infection and fungal skin infection. Siponimod may increase the risk in participants with active infections.
3. If participant received mRNA COVID-19 vaccination, must have received last dose at least 3 months prior to first dose of study drug/placebo.
4. Current evidence or history within the last 3 years of a neurological or psychiatric illness that could contribute to dementia, including (but not limited to) epilepsy, focal brain lesion, Parkinson's disease, seizure disorder, or head injury with loss of consciousness.
5. Meets DSM IV criteria for any major psychiatric disorder including psychosis, major depression and bipolar disorder.
6. Known history of self-reported alcohol and/ or substance abuse.
7. Isolated living circumstances which would prohibit a study partner from providing sufficient and credible information about the participant.
8. Poorly controlled hypertension
9. Known Atrioventricular heart block, known heart block type I-III.
10. History of myocardial infarction or signs or symptoms of unstable coronary artery disease within the last year (including revascularization procedure/angioplasty).
11. Severe pulmonary disease (including chronic obstructive pulmonary disease) requiring more than 2 hospitalizations within the past year.
12. Untreated obstructive sleep apnea.
13. Any thyroid disease (unless euthyroid on treatment for at least 6 months prior to screening). \[15\] Active neoplastic disease (except for skin tumors other than melanoma). Patients with a history of prior malignancy are eligible provided they were treated with curative intent and (i) do not require any longer any active therapy; (ii) being considered in complete remission; and (iii) after the Medical Monitor's assessment/approval of each case.
14. Prior prostate cancer or new diagnosis of prostate cancer.
15. History of multiple myeloma.
16. Absolute lymphocytopenia of \<1,000/mm3, or a history of lymphocytopenia.
17. Absolute neutropenia of \<1,000/mm3, or a history of neutropenia.
18. History of/ or current thromboembolism (including deep venous thrombosis).
19. Any clinically significant hepatic or renal disease (including presence of Hepatitis B or C surface antigen or an elevated transaminase levels of greater than 2x the upper limit of normal (ULN) or creatinine greater than 1.5 x upper limit of normal (ULN)).
20. Clinically significant hematologic or coagulation disorder including any unexplained anemia, or a platelet count less than 100,000/μL at screening.
21. Use of any investigational drug within 30 days or within five half-lives of the investigational agent, whichever is longer.
22. Unwilling or unable to undergo CT or MRI imaging.
23. In the opinion of the investigator, participation would not be in the best interest of the subject.
Minimum Eligible Age
50 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Texas Tech University Health Sciences Center
OTHER
Sponsor Role
collaborator
Arizona State University
OTHER
Sponsor Role
collaborator
National Institute on Aging (NIA)
NIH
Sponsor Role
collaborator
Novartis
INDUSTRY
Sponsor Role
collaborator
Laboratory Corporation of America
INDUSTRY
Sponsor Role
collaborator
St. Joseph's Hospital and Medical Center, Phoenix
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marwan N Sabbagh, MD
Role: PRINCIPAL_INVESTIGATOR
St. Joseph's Hospital and Medical Center, Phoenix
Boris Decourt, PhD
Role: STUDY_CHAIR
Texas Tech University Health Sciences Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kahle-Wrobleski K, Coley N, Lepage B, Cantet C, Vellas B, Andrieu S; Plasa DSA Group. Understanding the complexities of functional ability in Alzheimer's disease: more than just basic and instrumental factors. Curr Alzheimer Res. 2014 May;11(4):357-66. doi: 10.2174/1567205011666140317101419.
Reference Type
BACKGROUND
Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001 Mar;58(3):397-405. doi: 10.1001/archneur.58.3.397.
Reference Type
BACKGROUND
Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J; Alzheimer's Disease Neuroimaging Initiative. Staging Disease Severity Using the Alzheimer's Disease Composite Score (ADCOMS): A Retrospective Data Analysis. Neurol Ther. 2022 Mar;11(1):413-434. doi: 10.1007/s40120-022-00326-y. Epub 2022 Jan 31.
Reference Type
BACKGROUND
Decourt B, Wilson J, Ritter A, Dardis C, DiFilippo FP, Zhuang X, Cordes D, Lee G, Fulkerson ND, St Rose T, Hartley K, Sabbagh MN. MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. Open Access J Clin Trials. 2020;12:1-13. doi: 10.2147/oajct.s221914. Epub 2020 Jan 7.
Reference Type
BACKGROUND
Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):993-9. doi: 10.1136/jnnp-2015-312383. Epub 2016 Mar 23.
Reference Type
BACKGROUND
Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. doi: 10.1186/s13195-014-0089-7. eCollection 2014.
Reference Type
BACKGROUND
Tur C, Kalincik T, Oh J, Sormani MP, Tintore M, Butzkueven H, Montalban X. Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. Neurology. 2019 Oct 29;93(18):793-809. doi: 10.1212/WNL.0000000000008319. Epub 2019 Oct 7.
Reference Type
BACKGROUND
Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. gamma-Secretase inhibitors and modulators. Biochim Biophys Acta. 2013 Dec;1828(12):2898-907. doi: 10.1016/j.bbamem.2013.06.005. Epub 2013 Jun 17.
Reference Type
BACKGROUND
Frost GR, Jonas LA, Li YM. Friend, Foe or Both? Immune Activity in Alzheimer's Disease. Front Aging Neurosci. 2019 Dec 10;11:337. doi: 10.3389/fnagi.2019.00337. eCollection 2019.
Reference Type
BACKGROUND
Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines. 2019 Dec 9;7(4):97. doi: 10.3390/biomedicines7040097.
Reference Type
BACKGROUND
Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1257-70. doi: 10.1016/s0169-409x(02)00076-5.
Reference Type
BACKGROUND
Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012 Jan;2(1):a006346. doi: 10.1101/cshperspect.a006346.
Reference Type
BACKGROUND
Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27.
Reference Type
BACKGROUND
Sabbagh MN, Shi J, Lee M, Arnold L, Al-Hasan Y, Heim J, McGeer P. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings. BMC Neurol. 2018 Sep 26;18(1):155. doi: 10.1186/s12883-018-1160-y.
Reference Type
BACKGROUND
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov;141(11):1356-64. doi: 10.1176/ajp.141.11.1356.
Reference Type
BACKGROUND
Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):220-5. doi: 10.1097/01.wad.0000194014.43575.fd.
Reference Type
BACKGROUND
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4. doi: 10.1212/wnl.43.11.2412-a. No abstract available.
Reference Type
BACKGROUND
Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003 May-Aug;35(2-3):99-106. doi: 10.1081/dmr-120023681.
Reference Type
BACKGROUND
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.
Reference Type
BACKGROUND
Mauri M, Sinforiani E, Zucchella C, Cuzzoni MG, Bono G. Progression to dementia in a population with amnestic mild cognitive impairment: clinical variables associated with conversion. Funct Neurol. 2012 Jan-Mar;27(1):49-54.
Reference Type
BACKGROUND
Martinez B, Peplow PV. Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease. Neural Regen Res. 2019 Jul;14(7):1158-1176. doi: 10.4103/1673-5374.251192.
Reference Type
BACKGROUND
Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study. BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7.
Reference Type
BACKGROUND
Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998 Apr;150(2):296-304. doi: 10.1006/exnr.1997.6777.
Reference Type
BACKGROUND
Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013 Mar;75(3):831-41. doi: 10.1111/j.1365-2125.2012.04400.x.
Reference Type
BACKGROUND
Lannfelt L, Moller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther. 2014 Mar 24;6(2):16. doi: 10.1186/alzrt246. eCollection 2014.
Reference Type
BACKGROUND
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstrom E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.
Reference Type
BACKGROUND
Juif PE, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):879-95. doi: 10.1080/17425255.2016.1196188. Epub 2016 Jun 13.
Reference Type
BACKGROUND
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.
Reference Type
BACKGROUND
Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D, Petersen RC. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003 Jan 28;60(2):253-60. doi: 10.1212/01.wnl.0000042480.86872.03.
Reference Type
BACKGROUND
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5.
Reference Type
BACKGROUND
Goodman AD, Anadani N, Gerwitz L. Siponimod in the treatment of multiple sclerosis. Expert Opin Investig Drugs. 2019 Dec;28(12):1051-1057. doi: 10.1080/13543784.2019.1676725. Epub 2019 Nov 3.
Reference Type
BACKGROUND
Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehallier B, Channappa D, De Los Santos MB, McBride A, Pluvinage J, Elahi F, Tam GK, Kim Y, Greicius M, Wagner AD, Aigner L, Galasko DR, Davis MM, Wyss-Coray T. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature. 2020 Jan;577(7790):399-404. doi: 10.1038/s41586-019-1895-7. Epub 2020 Jan 8.
Reference Type
BACKGROUND
Gaser C, Franke K, Kloppel S, Koutsouleris N, Sauer H; Alzheimer's Disease Neuroimaging Initiative. BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer's Disease. PLoS One. 2013 Jun 27;8(6):e67346. doi: 10.1371/journal.pone.0067346. Print 2013.
Reference Type
BACKGROUND
Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z, Pal P, Li W, Shakeri-Nejad K. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects. Clin Pharmacokinet. 2019 Mar;58(3):349-361. doi: 10.1007/s40262-018-0700-3.
Reference Type
BACKGROUND
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9.
Reference Type
BACKGROUND
Fox R, Arnold D, Giovannoni G, Cree B, Vermersch P, Bar-Or A, Gold R, Benedict R, Meier DP, Arnould S, Ritter S, Dahlke F, Karlsson G, Kappos L (2020) Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130). Neurology 94:1130.
Reference Type
BACKGROUND
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
Reference Type
BACKGROUND
Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE. Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. J Alzheimers Dis. 2019;71(3):715-732. doi: 10.3233/JAD-190507.
Reference Type
BACKGROUND
Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020 Apr;19(4):336-347. doi: 10.1016/S1474-4422(19)30391-6. Epub 2020 Feb 11.
Reference Type
BACKGROUND
Decourt B, Drumm-Gurnee D, Wilson J, Jacobson S, Belden C, Sirrel S, Ahmadi M, Shill H, Powell J, Walker A, Gonzales A, Macias M, Sabbagh MN. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial. Curr Alzheimer Res. 2017;14(4):403-411. doi: 10.2174/1567205014666170117141330.
Reference Type
BACKGROUND
De Stefano N, Silva DG, Barnett MH. Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. CNS Drugs. 2017 Apr;31(4):289-305. doi: 10.1007/s40263-017-0415-2.
Reference Type
BACKGROUND
Crivelli SM, Giovagnoni C, Visseren L, Scheithauer AL, de Wit N, den Hoedt S, Losen M, Mulder MT, Walter J, de Vries HE, Bieberich E, Martinez-Martinez P. Sphingolipids in Alzheimer's disease, how can we target them? Adv Drug Deliv Rev. 2020;159:214-231. doi: 10.1016/j.addr.2019.12.003. Epub 2020 Jan 3.
Reference Type
BACKGROUND
Bordet R, Camu W, De Seze J, Laplaud DA, Ouallet JC, Thouvenot E. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. Rev Neurol (Paris). 2020 Jan-Feb;176(1-2):100-112. doi: 10.1016/j.neurol.2019.02.007. Epub 2019 Nov 19.
Reference Type
BACKGROUND
Bigaud M, Rudolph B, Briard E, Beerli C, Hofmann A, Hermes E, Muellershausen F, Schubart A, Gardin A. Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights. Mult Scler J Exp Transl Clin. 2021 Nov 3;7(4):20552173211049168. doi: 10.1177/20552173211049168. eCollection 2021 Oct.
Reference Type
BACKGROUND
Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, Simpson E, Appel S, Grasso DL, Mejia NI, Mateen F, Gill A, Vieira F, Tassinari V, Perrin S. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017 Dec;56(6):1077-1084. doi: 10.1002/mus.25733. Epub 2017 Aug 29.
Reference Type
BACKGROUND
Aytan N, Choi JK, Carreras I, Brinkmann V, Kowall NW, Jenkins BG, Dedeoglu A. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. Sci Rep. 2016 Apr 27;6:24939. doi: 10.1038/srep24939.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://pubmed.ncbi.nlm.nih.gov/35289055/
Additional citation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-500-037-10-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
NCT00602680
TERMINATED
PHASE2
A Phase I Study for Safety and Tolerability of AL002.
NCT03635047
COMPLETED
PHASE1
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301
RECRUITING
PHASE2
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
NCT03289143
TERMINATED
PHASE2
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
NCT00104013
COMPLETED
PHASE3
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
NCT06840054
NOT_YET_RECRUITING
PHASE2
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838
ACTIVE_NOT_RECRUITING
PHASE2
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896
COMPLETED
PHASE1
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
NCT01024660
COMPLETED
EARLY_PHASE1
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
NCT05792163
COMPLETED
PHASE1
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
NCT06964230
NOT_YET_RECRUITING
PHASE2/PHASE3
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
NCT03462121
COMPLETED
PHASE2
Senicapoc in Alzheimer's Disease
NCT04804241
RECRUITING
PHASE2
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
NCT00285025
COMPLETED
PHASE2
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
NCT01094340
UNKNOWN
PHASE2/PHASE3
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
NCT04669028
COMPLETED
PHASE3
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
NCT04491006
COMPLETED
PHASE2
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT02565511
TERMINATED
PHASE2/PHASE3
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
NCT00633841
COMPLETED
PHASE1
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
NCT02907567
COMPLETED
PHASE1/PHASE2
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
NCT00663936
COMPLETED
PHASE2
Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
NCT01723670
WITHDRAWN
PHASE2
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease
NCT01966666
COMPLETED
PHASE1
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
COMPLETED
PHASE2
Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients
NCT00842920
UNKNOWN
PHASE4